Galunisertib, a small molecule inhibitor of exogenous TGF-β Type I receptor, upregulates the expression of activated receptors DNAM-1, NKp30, and NKG2D on the surface of activated NK (aNK) cells in vitro, as well as the TNF-related apoptosis-inducing ligand (TRAIL), enhancing cytotoxicity and ADCC effects on neuroblastoma cells and improving therapeutic outcomes for neuroblastoma (114). This evidence concerns the gene CD226 and neuroblastoma.